

UNITED STA. 25 DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. s 1118A 05/31/90 ROBERTSON 07/531,179 EXAMINER KISHORE, G JAMES A. ARNO PAPER NUMBER ART UNIT PATENT DEPARTMENT ALCON LABORATORIES, INC. 6201 SOUTH FREEWAY 152 FORT WORTH, TX 76134 DATE MAILED: 04/15/91 This is a communication from the exeminer in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS A shortened statutory period for response to this action is set to expire ____3 __ month(s), _____ days from the date of this letter. Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133 Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION: 2. Notice re Patent Drawing, PTO-948. 1. Notice of References Cited by Examiner, PTO-892. 4. Notice of Informal Patent Application, Form PTO-152 3. Notice of Art Cited by Applicant, PTO-1449. 5. Information on How to Effect Drawing Changes, PTO-1474. Part II SUMMARY OF ACTION 1. Claims_ are pending in the application. Of the above, claims ______ 6 ___ 2 4 are withdrawn from consideration. 3. Claims 4. 🔀 Claims 1 - 5 5. Claims _____ are objecad to. 6. Claims are subject to restriction or election requirement. 7. This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes. 8. Formal drawings are required in response to this Office action. . 9. The corrected or substitute drawings have been received on . Under 37 C.F.R. 1.84 these drawings are acceptable; acceptable (see explanation or Notice re Patent Drawing, PTO-948). 10. The proposed additional or substitute sheet(s) of drawings, filed on ____ ____. has (have) been
approved by the examiner; disapproved by the examiner (see explanation). 11. The proposed drawing correction, filed ________ has been approved; disapproved (see explanation). 12. Acknowledgement is made of the claim for priority under U.S.C. 119. The certified copy has 🗆 been received 🗅 not been received been filed in parent application, serial no. _____; filed on _ 13. Since this application apppears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. 14. Other

EXAMINER'S

Serial No. 531,179

152

15.

16.

Art Unit

Applicants' amendment in paper no. 5 in which they confirm their election without traverse, of invention I, steroids as the species and dexamethasone as the ultimate species is acknowledged.

Upon reconsideration, the double patenting rejection of claims 1-5 under 35 U.S.C. 101 is withdrawn; upon reconsideration, the rejection of claims 1-5 under 35 U.S.C. 103 over Sanchez et al or Gurinder Singh is also withdrawn.

The following are the new rejections.

Claims 1-5 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-3 of U.S. Patent No. 4,939,135. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claim limitions encompass the claim limitations of said patent.

Claims 1-3 are rejected under 35 U.S.C. § 112, first paragraph, as the disclosure is enabling only for claims limited as set forth below. See M.P.E.P. §§ 706.03(n) and 706.03(z).

The term "a wound healing modulator is non enabling since it is unclear what it includes. The examiner suggests the inclusion of "dexamethasone" in claim 1 and cancellation of non elected

Serial No. 531,179

Art Unit 152

species in claim 2.

18.

Any inquiry concerning this communication should be directed to G.S.Kishore at telephone number (703) 308-2440.

Kishore: ltd April 09, 1991 (703) 308-2351t

